Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 41.0 Cr.
- Current Price ₹ 35.0
- High / Low ₹ 72.6 / 19.6
- Stock P/E 10.1
- Book Value ₹ 25.8
- Dividend Yield 0.00 %
- ROCE 16.9 %
- ROE 17.8 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 247 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 25.27 | 38.19 | |
| 20.53 | 31.58 | |
| Operating Profit | 4.74 | 6.61 |
| OPM % | 18.76% | 17.31% |
| 1.07 | 0.10 | |
| Interest | 0.65 | 0.54 |
| Depreciation | 0.72 | 0.74 |
| Profit before tax | 4.44 | 5.43 |
| Tax % | 40.77% | 25.41% |
| 2.62 | 4.05 | |
| EPS in Rs | 3.05 | 3.46 |
| Dividend Payout % | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 103% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 8.60 | 11.70 |
| Reserves | 6.66 | 18.43 |
| 12.66 | 12.35 | |
| 10.52 | 16.73 | |
| Total Liabilities | 38.44 | 59.21 |
| 10.35 | 10.13 | |
| CWIP | 0.15 | 2.22 |
| Investments | -0.00 | -0.00 |
| 27.94 | 46.86 | |
| Total Assets | 38.44 | 59.21 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -3.66 | -4.54 | |
| -0.34 | -2.35 | |
| 4.01 | 10.47 | |
| Net Cash Flow | 0.01 | 3.58 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 241.21 | 247.06 |
| Inventory Days | 244.39 | 228.39 |
| Days Payable | 281.81 | 356.77 |
| Cash Conversion Cycle | 203.80 | 118.69 |
| Working Capital Days | 74.24 | 135.14 |
| ROCE % | 16.88% |
Documents
Announcements
-
Copy of Newspaper Publication
3 September 2025 - Dispatch of 30th AGM notice and FY2024-25 annual report; newspaper ads published Sept 3, 2025.
-
Updates
2 September 2025 - 30th AGM on 25 Sep 2025; e-voting 22–24 Sep; cut-off 18 Sep; annual report link provided.
-
Shareholders meeting
2 September 2025 - 30th AGM on Sept 25, 2025 via VC; e-voting Sept 22–24; director Bal Kishan Gupta to retire and seek reappointment.
-
Updates
30 August 2025 - Corrigendum: voting rights cut-off date for AGM set as Thursday, September 18, 2025 (Medicamen Organics).
-
Updates
30 August 2025 - Corrigendum: AGM remote e-voting cut-off date is Thursday, September 18, 2025; other details unchanged.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.